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 INTRODUCTION
Forty to 50 percent of renal transplant sensitized 
recipients may have preformed anti-HLA-Cw antibodies. 
However, this frequency is lower than the reported 70 
to 80% for the other classical major human leukocyte 
antigen (HLA) Class I (A and B)1,2.
For many years anti-HLA-Cw antibodies were con-
sidered less immunogenic3 and were not considered 
in many organ allocation systems or immunologic risk 
stratification algorithms, including in Portugal.
More recently, with the development of more sensi-
tive assays to detect HLA antibodies, namely solid-
phase immunoassays, some clinical reports and retro-
spective studies have shown that HLA-C locus induces 
an antibody-mediated response similar to the other 
routinely checked loci2,4-7. The existence of preformed 
anti-HLA donor-specific antibodies (DSA) prior to trans-
plant increases the risk of antibody-mediated rejection 
(AMR)8 and is a factor contributing to poorer graft 
survival9. To address and highlight the importance of 
this subject we present a patient who had received a 
first kidney transplant and had preformed DSA anti-
HLA-Cw, developing AMR C4d+ soon after transplant.
 CASE REPORT
A 50-year-old caucasian female with end-stage renal 
disease due to polycystic kidney disease received a 
deceased kidney allograft transplant at our centre. She 
had started dialysis 3 years and 11 months prior. Regard-
ing possible sensitization events she had no history of 
previous organ transplantation or transfusions but had 
had 3 previous pregnancies. She underwent right 
nephrectomy 3 years earlier due to small abdominal 
cavity hampering implantation of a donor kidney.
The donor was a 56-year-old male with subarachnoid 
haemorrhage as cause of death. The recipient and the 
donor were both CMV-positive. The ABO blood type 
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of the donor and recipient was compatible, and the 
HLA alleles were mismatched at five loci: A1, B51, B62, 
DR4 and DR13 [Table I].
The crossmatch was negative in complement-
dependent cytotoxicity, negative in flow cytometry for 
B-cells (B-cell channel shift: 38, with cut-offs set at 80), 
but positive in flow cytometry for T-cells (B-cell channel 
shift: 69, with cut-offs set at 50). Cytotoxic PRA both 
in peak and last serum before transplant was 0%.
To determinate the specificity of the HLA antibodies, 
a single-antigen bead (SAB) assay (LabScreen Single 
Antigen Beads®, OneLambda, Canoga Park, CA) was 
performed in the patient. The MFI of each bead was 
measured using LABScanTM 100 flow analyzer 
(Luminex®, Austin, TX, USA). The analysis was performed 
using HLA fusion® software (One Lambda Inc.) and a 
cut-off for a positive reaction set at MFI value of ≥1000.
Several anti-HLA antibodies were identified: B13-
8217, Cw6-4445, Cw18-4086, Cw15-3961, Cw17-3466, 
Cw5-3306, Cw2-2851, Cw4-1621, but only the Cw2 was 
donor-specific.
Immunosuppressive treatment included antithymo-
cyte globulin (3 mg/kg for 7 days), tacrolimus (FK-506, 
0.1 mg/kg/day, and the dose was adjusted to maintain 
a trough level in whole blood between 8 and 12 ng/ml 
during the first month), mycophenolate mofetil (started 
at a dose of 2000 mg/day) and corticosteroids (meth-
ylprednisolone was administered intravenously at doses 
of 500, 250 and 125 mg/day on the day of transplanta-
tion, days 1-2 and days 3-4 after the operation, respec-
tively; oral prednisolone was started on day 5 after the 
operation at the dose of 20 mg, then tapered to 15 
mg/day within first month after transplant).
Surgery went well, with no reported intraoperative 
complications. Ureterocystostomy was protected by a 
JJ-stent. The patient started diuresis immediately post-
operative. Low blood pressure and a haemoglobin fall of 
3grams/dL were detected in the hours following surgery, 
but there was no active bleeding identified by ultrasound. 
The patient responded to fluids and 2 units of red blood 
cells. On the subsequent days, the allograft evolved with 
good early function and the patient was discharged after 
8 days with serum creatinine level of 1.01 mg/dL.
Three days after discharge, she presented asympto-
matic to her routine first transplant consultation but 
with de novo increased serum creatinine (level 2.93 
mg/dL) and urea of 198 mg/dL. Tacrolimus levels were 
within the range. Renal sonography revealed good con-
trast resolution between cortex and medulla, no signs 
of dilatation of the collecting system, with pig-tail cath-
eter correctly positioned. She was admitted and a renal 
allograft biopsy was performed.
The biopsy findings were highly indicative of acute 
AMR with glomerulitis (g2), peri-tubular capillaritis 
(ptc2), diffuse acute tubular injury and linear diffuse 
positive C4d staining at peritubular capillaries.
Repeated testing using Luminex® SAB assay was 
performed (for Class I and Class II antigens) on the 
serum samples from day 1 of the current admission.
We repeated the crossmatch and this time it was 
positive in flow cytometry for B-cells (B-cell channel 
shift: 69, with cut-offs set at 80), and positive in flow 
cytometry for T-cells (B-cell channel shift: 143, with 
cut-offs set at 50).
Three DSA were detected against HLA-B51 (with a 
MFI of 8878), against HLA-B62 (with a MFI of 4374) 
and again against HLA-Cw2 (with an increase of MFI 
from 2851 to 8321) – Table II. The C1q fixation capacity 
of anti-HLA antibodies by Luminex C1q assay was not 
performed.
The clinical and histological findings were consistent 
with an acute AMR, as established by the Banff 
criteria10.
She was treated with methylprednisolone (500 mg 
bolus) for 3 days, plasmapheresis (7 sessions every 
Table I
HLA alleles from the patient and the donor.
A1 A2 B1 B2 C1 C2 DR1 DR2
Patient 2 29 60 44 10 16 1 7
Donor 1 2 62 51 2 9 4 13 
Table II
Donor specific antibodies (DSA) detected prior to transplant and after 
transplant.
B51 B62 Cw2
Pretransplant Not detected Not detected 2851
Admission for AKI 8878 4347 8321
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other day) in combination with intravenous immuno-
globulin (IvIg) 100 mg/kg after each session. After the 
last plasmapheresis session, she received high-dose 
IvIg (2 g/kg) divided into four daily doses, followed by 
one dose of rituximab (375 mg/m2); a similar dose of 
IvIg (2 g/kg) was repeated 1 and 3 months later.
Six months after, her graft function was recovered 
to serum creatinine 1.1 mg/dL without proteinuria.
 DISCUSSION
Preformed human leukocyte antigen (HLA) donor 
specific antibodies (DSA) have been shown to increase 
the risk of antibody-mediated rejection (AMR) and have 
a deleterious effect on kidney graft survival11,12. Clas-
sically, antibodies to major HLA Class I (A and B) and 
Class II (DR and DQ) are considered to be responsible 
for the majority of the cases of AMR. For many years 
HLA-Cw antigens were considered less immunogenic 
and neglected in the matching algorithms of most kid-
ney allocation systems. HLA-Cw molecules are poorly 
expressed at the cell surface compared with HLA-A and 
HLA-B locus products, but intracellular HLA-A, HLA-B 
and HLA-Cw alleles are expressed in similar amounts13,14. 
One reason suggested for this low expression at the 
cell surface is the fact that HLA-Cw alleles interact stably 
with the transporter associated with antigen processing 
(TAP) and they are retained in the endoplasmic reticu-
lum, where they are degraded13. An additional explana-
tion for the poor HLA-Cw cell surface expression, sug-
gested by McCutcheon et al.14, is that HLA-Cw heavy 
chain mRNA is instable and rapidly degraded, resulting 
in a lower rate of protein. Those facts, in association 
with the modest sensitivity of the lymphocytotoxicity-
based assays used for screening and identification of 
HLA-Cw antigens are the main reason for their disre-
gard. In spite of their frequency being lower, with 
reports of around 50% sensitization to HLA-Cw, and 
around 80% to HLA-A and HLA-B1,2, some reports have 
been published concerning their association with AMR 
and impact on graft function and survival5,15,16.
Gilbert et al. compared two groups of pretransplant 
immunized recipients, one with only classical HLA-A, 
-B, -DR, -DQ antibodies (n = 176) and the other group 
with classical plus HLA-C and/or -DP antibodies (n = 
27)4. They concluded that there was a significant 
increase in the number of AMR and graft losses for 
immunologic reasons among the group with pretrans-
plant anti-Cw and -DP antibodies. However, they did 
not distinguish between pretransplant anti-DP or anti-
Cw antibodies, and they speculated that anti-DP anti-
bodies seemed to be involved more frequently in 
poorer graft outcomes. Ling et al. investigated the clini-
cal outcomes in kidney transplant recipients with iso-
lated donor-specific anti-HLA-Cw antibodies2. They 
identified eight patients with pretransplant DSA anti-
HLA-Cw, exclusively. During a 6-month median of fol-
low-up (range 3–24 months), patient and graft survival 
was 100% without any acute rejection occurring. In 
this group, all the patients had induction therapy with 
thymoglobulin or basiliximab and additionally all 
patients received intravenous immunoglobulin, similar 
to patients with positive flow cytometry crossmatch 
(FCXM) and/or cPRA>50%. Even so, the median time 
of follow-up was relatively short and may have under-
estimated the incidence of rejection. Aubert et al. 
evaluated retrospectively 22 renal transplant recipients 
with isolated anti-HLA-Cw DSA at day 0 of renal trans-
plant, comparing them with 88 allo-sensitized patients 
with no preformed DSA (control group), and followed 
for a period of 1 year17. Acute AMR was diagnosed in 
six patients (27.3%) with DSA-Cw versus 9% in those 
without DSA. In this study, the patients with DSA anti-
HLA-Cw received less-intensive immunosuppression 
than the control group of immunized patients, including 
ATG induction (only 59.1%), and this may probably be 
a plausible explanation for this high rate of AMR. How-
ever, they alert for the necessity of screening pretrans-
plant DSA HLA-Cw and subsequent modulation of 
immunosuppression in cases of positivity. More recent-
ly, Bachelet el al. analyzed the clinical impact of DSA 
anti-HLA-Cw and/or -DP through a retrospective study, 
comparing 48 patients transplanted with isolated pre-
formed DSA anti-HLA-Cw and/or –DP with a group of 
HLA-sensitized recipients with no DSA (104 patients) 
and 47 kidney transplant recipients with preformed 
DSA anti-HLA-A, −B, −DR, and/or –DQ18. Two years after 
transplantation, the groups with DSA (both Cw/DP or 
A/B/DR/DQ) had similar incidence of AMR and graft 
survival (and worse than the group with no DSA), show-
ing that preformed DSA anti–HLA-Cw and/or -DP were 
as deleterious as DSA anti–HLA A/B/DR/DQ.
Concerning immunological risk assessment in trans-
plantation, we know that DSA levels measured as mean 
fluorescence intensity (MFI) and flow cytometry cross-
match channel shift values increased our ability to 
stratify the development of AMR; both techniques were 
performed in our patient. Another procedure that has 
prognostic value for AMR occurrence is the detection 
of complement-fixing anti-HLA antibodies, which is the 
first step in the activation of the classical complement 
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cascade, namely the Luminex C1q assay. Akalin et al. 
showed recently that C1q DSA was associated with 
acute and chronic AMR and is important in the identi-
fication of atients at risk for antibody-mediated allograft 
injury19. However in our patient this test was not per-
formed since it is not part of the protocol and the costs 
are significant.
In our clinical case, despite induction immunosup-
pressive therapy with high dose of thymoglobulin, we 
witnessed an increase in the titer of preformed DSA 
anti-HLA Cw2 and the onset of de novo DSA soon after 
transplantation. We believe that the preformed DSA 
anti-HLA-Cw present before transplantation and the 
association with AMR occurrence is clear in our patient, 
with data from literature confirming that their presence 
is as deleterious as DSA anti–HLA A/B/DR/DQ. There-
fore, HLA-C typing and respective antibody identifica-
tion will benefit sensitized patients during organ alloca-
tion and will allow us to use induction therapy or 
desensitization strategies properly.
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